PL Capital Initiates 'Buy' Rating on Sai Lifesciences
1 report, 1 independent
Updated Oct 23
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PL Capital initiated coverage on Sai Lifesciences with a 'Buy' rating and a target price of ₹1,620 per share. The brokerage firm noted that Sai Lifesciences is well positioned to benefit from increasing pharmaceutical outsourcing, supported by its integrated contract research, development and manufacturing organisation platform.
From livemint.com
Why it matters
The rating suggests confidence in Sai Lifesciences' ability to strengthen revenue visibility by supporting pharmaceutical and biotechnology companies across a molecule’s lifecycle. The brokerage views large pharmaceutical companies as a key near-term growth driver for the company.
PL Capital remains constructive on domestic equities.
From livemint.com